Placental health in late pregnancy linked to childhood ADHD - News-Medical
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
Attention deficit/hyperactivity disorder (ADHD) in children may be associated with problems with the health of the placenta during late pregnancy, according to a new study by University of Iowa Health Care researchers. The findings, published in JAMA Psychiatry, help to identify a risk factor in pregnancy that is linked to ADHD in children, and potentially points to new treatment targets for ADHD.
ADHD is a common neurodevelopmental condition that affects up to 10% of American children between the ages of 3 and 17. The symptoms of ADHD, including problems with paying attention, hyperactivity, and impulsivity, can negatively impact many aspects of a person's life, including academic and professional achievement. However, there is a lack of understanding about the potential causes of this neurodevelopmental condition.
This article is an excerpt. To read the full content, visit the original source. News-Medical
Related articles
Micro- and nanoplastics in pediatric health: from placental transfer to neurodevelopmental outcomes - Nature
Medley, E. A. et al. A systematic review of the placental translocation of micro- and nanoplastics. Curr. Environ. Health Rep. 10, 99–111 (2023). Article Ragusa, A. et al. Plasticenta: first evidence of microplastics in human placenta. EnvironInt 146, 106274 (2021). CAS
Bioengineer.org | Switching HIV drugs or adding zoledronic acid rebuilds bone lost to tenofovir - European AIDS Treatment Group
Bioengineer.org news storyFor millions of people living with HIV, antiretroviral therapy has transformed a once-fatal infection into a manageable chronic condition. Yet the very drugs that suppress the virus can carry quiet costs, and one of the most insidious is bone loss. Tenofovir disoproxil fumarate, or TDF, has been a cornerstone of HIV treatment worldwide for two decades, prized for its potency, durability, and low cost. But a growing body of evidence has linked TDF exposure to measurable reductions in bone mineral density, raising an increasingly urgent clinical question: once bone has been lost on a TDF-based regimen, can it be recovered? A new prospective cohort study, published in BMC Infectious Diseases, offers some of the most detailed longitudinal evidence to date that the answer, for many patients, is yes. The research team enrolled 223 virologically suppressed men living with HIV who had low bone mineral density while taking TDF-based antiretroviral therapy.
0 comments
No comments yet. Be the first to share your thoughts!